Journal of the National Cancer Center最新文献

{"title":"Growing research and development of targeted anticancer drugs in China","authors":"Huiyao Huang ,&nbsp;Jingting Du ,&nbsp;Xinyu Meng ,&nbsp;Dawei Wu ,&nbsp;Yue Yu ,&nbsp;Shuhang Wang ,&nbsp;Lili Wang ,&nbsp;Wenya Wang ,&nbsp;Yu Tang ,&nbsp;Ning Li","doi":"10.1016/j.jncc.2023.02.004","DOIUrl":"10.1016/j.jncc.2023.02.004","url":null,"abstract":"<div><h3>Objective</h3><p>To deliver a comprehensive picture of the landscape and changing trend of trials and approvals on targeted anticancer drugs in China from 2012 to 2021.</p></div><div><h3>Methods</h3><p>Trials, investigated products, and listed drugs were acquired from national databases. The status quo, changing trend of absolute number, and proportion of targeted trials, products, and drugs, as well as the corresponding difference between domestic and foreign companies were analyzed.</p></div><div><h3>Results</h3><p>A total of 2,632 trials on 1,167 targeted antitumor drugs were identified, accounting for 81.5% of all registered trials. The number and proportion of trials on targeted drugs increased steadily, with an average growth rate of 36.0% and 6.2%, respectively. A similar growth trend was observed in the number (33.7%) and proportion (13.8%) of targeted drugs. Targeted drugs and trials owned by domestic companies accounted for a higher proportion than that by foreign companies (80.5% vs. 19.5%; 83.2% vs. 16.8%, respectively), and the growing trend for both targeted drugs (13.8% vs. 5.7%) and trials (13.8% vs. 33.7%) owned by domestic companies was faster. The proportion of targeted drug trials (80.5% vs. 85.6%) and multicenter trials (6.0% vs. 69.9%) initiated by domestic companies was lower than that by foreign companies, with the gap gradually narrowing. Among the identified 18 targets of the 126 immune drugs under development, only one globally new target was found.</p></div><div><h3>Conclusions</h3><p>Research and development of targeted antitumor drugs in China are booming and advancing rapidly, and domestic enterprises have become the pillar. Encouraging genomics activities and establishing incentives and public–private collaboration frameworks are crucial for innovation-oriented drug development in China.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"3 2","pages":"Pages 129-134"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48655283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of life and survival outcomes of patients with inoperable esophageal squamous cell carcinoma after definitive radiation therapy: A multicenter retrospective observational study in China from 2015 to 2016","authors":"Xin Wang ,&nbsp;Fei Liang ,&nbsp;Xiaomin Wang ,&nbsp;Ye Wu ,&nbsp;Dejun Wang ,&nbsp;Yunjie Cheng ,&nbsp;Jiao Li ,&nbsp;Yougai Zhang ,&nbsp;Bochen Sun ,&nbsp;Yu Lin ,&nbsp;Dandan Yu ,&nbsp;Xiaolin Ge ,&nbsp;Jingyi Shen ,&nbsp;Guangyue Yao ,&nbsp;Lei Wu ,&nbsp;Jihong Zhang ,&nbsp;Wei Jiang ,&nbsp;Nan Bi ,&nbsp;Zhilong Yu ,&nbsp;Qifeng Wang ,&nbsp;Luhua Wang","doi":"10.1016/j.jncc.2023.05.001","DOIUrl":"10.1016/j.jncc.2023.05.001","url":null,"abstract":"<div><h3>Objectives</h3><p>To investigate the health-related quality of life (HRQL) of long-term survivors of inoperable esophageal squamous cell carcinoma (ESCC) treated with definitive radiation therapy, the real-world trends in the use of advanced radiation techniques, and their impact on the survival outcomes of ESCC patients.</p></div><div><h3>Methods</h3><p>In this multicenter retrospective observational study, the medical records related to demographics and treatment of ESCC patients who were treated with definitive radiation therapy at 14 provincial hospitals in China from 1 January 2015 to 31 December 2016 were analyzed. A HRQL questionnaire was completed by survivors and collected by doctors at the final follow-up. The difference in quality of life between patients with or without recurrence was compared using the Wilcoxon–Mann–Whitney test. Overall survival (OS) was estimated using the Kaplan–Meier method and the group differences were assessed by unstratified log-rank test. The Cox proportional hazards model with Efron's method of tie handling was used to calculate the risk factors for OS.</p></div><div><h3>Results</h3><p>The data of a total of 3,308 patients were collected for this study, 248 were excluded because of missing data, and a final of 3,060 patients were included in the analysis. Most patients (2,901; 94.8%) received intensity-modulated radiotherapy (IMRT)/volumetric-modulated arc therapy (VMAT)/tomotherapy (TOMO). The 5-year OS rate was 30%. Patients who received either two-dimensional radiotherapy (2DRT; HR, 2.43 [95% CI, 1.70–3.47]; <em>P &lt;</em> 0.001) or three-dimensional radiotherapy (3DRT; HR, 1.45 [95% CI, 1.14–1.84]; <em>P</em> = 0.003) had a significantly increased risk of death compared to those who received IMRT/VMAT/TOMO. Of the 716 (23.4%) long-term survivors who completed the HRQL questionnaire, nearly 70% patients were still able to swallow normally or almost normally, and &gt;80% patients did not experience weight loss. Nearly 80% patients found life very enjoyable or were fairly enjoying life.</p></div><div><h3>Conclusions</h3><p>This large, multicenter retrospective study on ESCC patients who received definitive radiation therapy found that most ESCC survivors are satisfied with their quality of life. Most patients received advanced radiation technology. Patients who received either 2DRT or 3DRT had a significantly increased risk of death compared to those who received advanced radiation technology.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"3 2","pages":"Pages 150-158"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48644378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Minimally invasive versus open esophagectomy for resectable thoracic esophageal cancer (NST 1502): a multicenter prospective cohort study","authors":"Yousheng Mao ,&nbsp;Shugeng Gao ,&nbsp;Yin Li ,&nbsp;Chun Chen ,&nbsp;Anlin Hao ,&nbsp;Qun Wang ,&nbsp;Lijie Tan ,&nbsp;Jianqun Ma ,&nbsp;Gaoming Xiao ,&nbsp;Xiangning Fu ,&nbsp;Wentao Fang ,&nbsp;Zhigang Li ,&nbsp;Yongtao Han ,&nbsp;Keneng Chen ,&nbsp;Renquan Zhang ,&nbsp;Xiaofei Li ,&nbsp;Tiehua Rong ,&nbsp;Jianhua Fu ,&nbsp;Yongyu Liu ,&nbsp;Weimin Mao ,&nbsp;Jie He","doi":"10.1016/j.jncc.2023.02.002","DOIUrl":"https://doi.org/10.1016/j.jncc.2023.02.002","url":null,"abstract":"<div><h3>Background</h3><p>Whether minimally invasive esophagectomy (MIE) is superior to open esophagectomy (OE) in the treatment of esophageal squamous cell carcinoma (ESCC) is still uncertain. Therefore, this multicenter prospective study aimed to compare MIE with OE in postoperative parameters and long-term survival.</p></div><div><h3>Methods</h3><p>All hospitalized patients with cT1b-3N0–1M0 thoracic ESCC treated by MIE or OE were enrolled from 19 selected centers from April 1, 2015 to December 31, 2018. The propensity score matching (PSM) was performed to minimize the selection bias. The basic clinicopathological characteristics and 3-year overall survival (OS) as well as disease-free survival (DFS) of two groups were compared by R version 3.6.2.</p></div><div><h3>Results</h3><p>MIE were performed in 1,387 patients and OE in 335 patients. 335 cases in each group were finally matched by PSM, and no significant differences in the essential demographic characteristics were observed between the MIE and OE groups after PSM. Compared with OE, MIE had significantly less intraoperative bleeding, less total drainage volume, shorter postoperative hospital stay, and harvested significantly more lymph nodes (LNs) (all <em>P</em> &lt; 0.001). There were no significant differences in the major postoperative complications and death rates between MIE and OE. The 3-year OS and DFS were 77.0% and 68.1% in the MIE group versus 69.3% and 60.9% in the OE group (OS: <em>P</em> = 0.03; DFS: <em>P</em> = 0.09), and the rates were 75.1% and 66.5% in the MIE group versus 66.9% and 58.6% in the OE group for stage cII patients (OS: <em>P</em> = 0.04, DFS: <em>P</em> = 0.09), respectively.</p></div><div><h3>Conclusions</h3><p>Compared with OE, MIE is a safe and effective treatment approach with similar mortality and morbidity. It has the advantages in harvesting more LNs, improving postoperative recovery and survival of stage cII ESCC patients.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"3 2","pages":"Pages 106-114"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49736946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Docetaxel plus S-1 versus docetaxel plus capecitabine as first-line treatment for advanced breast cancer patients: a prospective randomized phase II study","authors":"Nilupai Abudureheiyimu ,&nbsp;Yun Wu ,&nbsp;Qing Li ,&nbsp;Pin Zhang ,&nbsp;Fei Ma ,&nbsp;Peng Yuan ,&nbsp;Yang Luo ,&nbsp;Ying Fan ,&nbsp;Shanshan Chen ,&nbsp;Ruigang Cai ,&nbsp;Qiao Li ,&nbsp;Yiqun Han ,&nbsp;Hangcheng Xu ,&nbsp;Yan Wang ,&nbsp;Jiayu Wang ,&nbsp;Binghe Xu","doi":"10.1016/j.jncc.2023.05.003","DOIUrl":"10.1016/j.jncc.2023.05.003","url":null,"abstract":"<div><h3>Background</h3><p>This study was conducted to evaluate the efficacy and safety of docetaxel/S-1 (TS) compared with docetaxel/capecitabine (TX) as a first-line treatment for advanced breast cancer.</p></div><div><h3>Methods</h3><p>Patients with advanced metastatic breast cancer were randomly divided into the TS group (n = 54) and the TX group (n = 57) for first-line chemotherapy from August 2015 to April 2019 (ClinicalTrials.org registration no. NCT02947061). Following the completion of combination therapy, patients without progression received S-1 or capecitabine maintenance treatment. The primary end point was progression-free survival (PFS).</p></div><div><h3>Results</h3><p>Among 111 enrolled patients, the median PFS did not differ significantly between the TS group and the TX group (TS vs. TX, 9.0 vs. 7.4 months, <em>P</em> = 0.365, 95% confidence interval [CI]: 0.50–1.11, hazard ratio [HR]: 0.75). There was also no statistically significant difference in median overall survival (OS) between the two groups (TS vs. TX, 40.2 vs. 41.3 months, <em>P</em> = 0.976). In addition, visceral metastasis and metastasis sites, such as the liver or lung, did not lead to a significant effect on PFS and OS. The two regimens showed no significant difference in adverse events, except hand-foot syndrome, which predominated in the TX group (38.6% vs. 7.4%, <em>P</em> = 0.001), and diarrhea (24.1% vs. 3.6%, <em>P</em> = 0.003) and elevation of aspartate aminotransferase (AST)/alanine aminotransferase (ALT) levels (14.8% vs. 3.5%, <em>P</em> = 0.049), which were more frequent in the TS group.</p></div><div><h3>Conclusions</h3><p>The TS and TX regimens demonstrated similar efficacy and safety for the first-line treatment of advanced breast cancer. The TS regimen had fewer cases of severe hand-foot syndrome than the TX regimen, representing an effective alternative option to the TX regimen. Further studies are warranted to define the efficacy and safety of this strategy in real-world settings.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"3 2","pages":"Pages 115-120"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46631963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intelligent oncology: The convergence of artificial intelligence and oncology","authors":"Bo Lin ,&nbsp;Zhibo Tan ,&nbsp;Yaqi Mo ,&nbsp;Xue Yang ,&nbsp;Yajie Liu ,&nbsp;Bo Xu","doi":"10.1016/j.jncc.2022.11.004","DOIUrl":"10.1016/j.jncc.2022.11.004","url":null,"abstract":"<div><p>With increasingly explored ideologies and technologies for potential applications of artificial intelligence (AI) in oncology, we here describe a holistic and structured concept termed intelligent oncology. Intelligent oncology is defined as a cross-disciplinary specialty which integrates oncology, radiology, pathology, molecular biology, multi-omics and computer sciences, aiming to promote cancer prevention, screening, early diagnosis and precision treatment. The development of intelligent oncology has been facilitated by fast AI technology development such as natural language processing, machine/deep learning, computer vision, and robotic process automation. While the concept and applications of intelligent oncology is still in its infancy, and there are still many hurdles and challenges, we are optimistic that it will play a pivotal role for the future of basic, translational and clinical oncology.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"3 1","pages":"Pages 83-91"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43602221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Activation of the complement system sensitizes immune checkpoint blockade","authors":"Fei Shao ,&nbsp;Yannan Yang ,&nbsp;Zhimin Lu ,&nbsp;Jie He","doi":"10.1016/j.jncc.2022.11.005","DOIUrl":"10.1016/j.jncc.2022.11.005","url":null,"abstract":"","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"3 1","pages":"Pages 4-6"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45005800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Personalized precision radiotherapy and its evolving role for human papillomavirus-positive oropharyngeal cancer","authors":"Hayden Ansinelli,&nbsp;Chris Gay,&nbsp;Steven Nguyen,&nbsp;Christopher M. Morrison,&nbsp;Jared R. Robbins","doi":"10.1016/j.jncc.2022.11.006","DOIUrl":"10.1016/j.jncc.2022.11.006","url":null,"abstract":"<div><p>Human papilloma virus (HPV)-associated oropharyngeal cancer (OPC) is a unique entity with increased responsiveness to treatment and excellent oncologic outcomes. The purpose of this narrative review is to highlight how an improved prognosis for HPV (+) tumors and an ever-increasing understanding of the risk factors, risk stratification, and areas of potential spread are shaping management options. Additionally, we aim to detail how advances in treatment technology on both the surgical and radiation fronts are facilitating the delivery of increasingly personalized and precise treatments. This review will describe key aspects of recent and currently-ongoing trials investigating the de-escalation and individualization of treatment in this patient cohort, and how they are building a foundation for distinct treatment paradigms for HPV (+) tumors. Further studies into the integration of biomarker-guided treatments combined with clinical trial enrollment will help ensure a future of personalized treatments and improved outcomes, both in terms of oncologic outcomes and toxicity, for patients with HPV (+) OPC.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"3 1","pages":"Pages 72-82"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48843987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum to ‘Evolution and genotypic characteristics of small cell lung cancer transformation in non-small cell lung carcinomas’ [Journal of the National Cancer Center, 1 (2021), 4: 153-162]","authors":"Jia Zhong ,&nbsp;Xiaoting Li ,&nbsp;Zhijie Wang ,&nbsp;Jianchun Duan ,&nbsp;Wenbin Li ,&nbsp;Minglei Zhuo ,&nbsp;Tongtong An ,&nbsp;Ziping Wang ,&nbsp;Tiantian Gu ,&nbsp;Yuyan Wang ,&nbsp;Hua Bai ,&nbsp;Yan Wang ,&nbsp;Meina Wu ,&nbsp;Zhikun Zhao ,&nbsp;Xin Yang ,&nbsp;Zhe Su ,&nbsp;Xiang Zhu ,&nbsp;Rui Wan ,&nbsp;Jianjie Li ,&nbsp;Jie Zhao ,&nbsp;Jie Wang","doi":"10.1016/j.jncc.2022.11.001","DOIUrl":"10.1016/j.jncc.2022.11.001","url":null,"abstract":"","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"3 1","pages":"Page 92"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41765416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ready for ctDNA-guided treatment decisions in colorectal cancer?","authors":"Jiaolin Zhou,&nbsp;Guole Lin","doi":"10.1016/j.jncc.2022.10.003","DOIUrl":"10.1016/j.jncc.2022.10.003","url":null,"abstract":"","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"3 1","pages":"Pages 1-3"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44111835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patterns and trends in esophageal cancer incidence and mortality in China: An analysis based on cancer registry data","authors":"Ru Chen ,&nbsp;Rongshou Zheng ,&nbsp;Siwei Zhang ,&nbsp;Shaoming Wang ,&nbsp;Kexin Sun ,&nbsp;Hongmei Zeng ,&nbsp;Li Li ,&nbsp;Wenqiang Wei ,&nbsp;Jie He","doi":"10.1016/j.jncc.2023.01.002","DOIUrl":"10.1016/j.jncc.2023.01.002","url":null,"abstract":"<div><h3>Background</h3><p>Esophageal cancer poses a significant global burden, while its patterns and trends remain to be clarified. The aim of this study is to provide an update on the incidence and mortality rates of esophageal cancer and their trends in China based on data from the National Cancer Registry.</p></div><div><h3>Methods</h3><p>We extracted data from the National Central Cancer Registry (NCCR) of China from 2000 to 2016 and performed comprehensive quality control. We calculated age-standardized rates of China (ASR China) and world (ASR world) using the Chinese population in 2000 and the Segi's world standard population, and performed a joinpoint regression analysis to examine the trend in incidence and mortality of esophageal cancer. The annual percent change (APC) and weighted average APC (AAPC) over the entire study period were estimated to measure the changing trend. Subgroup analyses were conducted by sex, region and pathological type.</p></div><div><h3>Results</h3><p>A total of 487 eligible cancer registries were included in the data analysis and 22 registries with uninterrupted registration data were used for trend analysis. In 2016, there were an estimated of 184,500 incident cases of esophageal cancer and 142,300 deaths in China. The crude incidence, ASR China and ASR world were 25.25/100,000, 11.00/100,000 and 11.13/100,000, respectively. And the crude mortality, ASR China and ASR world were 19.38/100,000, 8.25/100,000 and 8.28/100,000, respectively. Esophageal squamous cell carcinoma (ESCC) was the most common histological type, accounting for 85.79% of all cases, followed by esophageal adenocarcinoma (EAC) (11.00%) and others (3.21%). There was a decreasing trend of ASR world in incidence and mortality during 2000–2016 with the AAPC of -4.6% (95% CI: -5.7%, -3.4%) and -4.6% (95% CI: -5.2%, -3.9%). The pattern and trend of esophageal cancer differ in sex, region and pathological type.</p></div><div><h3>Conclusions</h3><p>The burden of esophageal cancer in China remains high with sex, regional and subtype differences. The incidence and mortality of esophageal cancer have continued to decline over the past decade, which was due in part to the reductions in risk factor exposure and the implementation of screening.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"3 1","pages":"Pages 21-27"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45932408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}